Bydureon Bcise

Physical Activity, Type 2 Diabetes, Diet

Treatment

0 Active Studies for Bydureon Bcise

Treatment for

Physical Activity

What is Bydureon Bcise

ExenatideThe Generic name of this drug

Treatment SummaryExenatide is a medication used to control blood sugar levels. It works by activating the GLP-1 receptor, which increases insulin secretion, lowers glucagon secretion, and slows digestion. Exenatide was approved by the FDA in 2005.

Byettais the brand name

image of different drug pills on a surface

Bydureon Bcise Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Byetta

Exenatide

2005

Effectiveness

How Bydureon Bcise Affects PatientsExenatide helps the body to better regulate its response to glucose. This means when glucose is present, insulin is released in the right amount and glucagon is released in a lower amount. During hypoglycemia, the normal amount of glucagon is still released. Additionally, exenatide slows down how quickly the stomach empties, leading to a slower and more controlled release of glucose into the body. These effects help to prevent both high and low blood sugar levels.

How Bydureon Bcise works in the bodyExenatide is a drug that helps control blood sugar levels. It does this by activating a certain receptor in the body, which then increases the production of insulin and decreases the production of glucagon. These hormones help regulate glucose levels in the body. Exenatide also slows down how quickly food leaves the stomach, which helps keep blood sugar levels steady. All of these effects work together to help prevent both high and low blood sugar.

When to interrupt dosage

The recommended quantity of Bydureon Bcise relies upon the diagnosed situation. The degree of dosage fluctuates, in light of the administration method delineated in the table below.

Condition

Dosage

Administration

Physical Activity

, 0.25 mg/mL, 0.005 mg, 0.01 mg, 2.0 mg, 20.0 mg/mL, 2.0 mg/dose, 0.005 mg/pump actuation, 0.01 mg/pump actuation

, Subcutaneous, Injection, Injection - Subcutaneous, Kit, Injection, solution, Injection, solution - Subcutaneous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Subcutaneous, Solution, Solution - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Subcutaneous, Injection, suspension, extended release, Injection, suspension, extended release - Subcutaneous, Suspension, extended release, Suspension, extended release - Subcutaneous

Type 2 Diabetes

, 0.25 mg/mL, 0.005 mg, 0.01 mg, 2.0 mg, 20.0 mg/mL, 2.0 mg/dose, 0.005 mg/pump actuation, 0.01 mg/pump actuation

Diet

, 0.25 mg/mL, 0.005 mg, 0.01 mg, 2.0 mg, 20.0 mg/mL, 2.0 mg/dose, 0.005 mg/pump actuation, 0.01 mg/pump actuation

Warnings

Bydureon Bcise Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Exenatide may interact with Pulse Frequency

There are 20 known major drug interactions with Bydureon Bcise.

Common Bydureon Bcise Drug Interactions

Drug Name

Risk Level

Description

(R)-warfarin

Moderate

Exenatide can cause an increase in the absorption of (R)-warfarin resulting in an increased serum concentration and potentially a worsening of adverse effects.

(S)-Warfarin

Moderate

Exenatide can cause an increase in the absorption of (S)-Warfarin resulting in an increased serum concentration and potentially a worsening of adverse effects.

2,4-thiazolidinedione

Moderate

The risk or severity of hypoglycemia can be increased when Exenatide is combined with 2,4-thiazolidinedione.

4-hydroxycoumarin

Moderate

Exenatide can cause an increase in the absorption of 4-hydroxycoumarin resulting in an increased serum concentration and potentially a worsening of adverse effects.

AICA ribonucleotide

Moderate

The risk or severity of hypoglycemia can be increased when Exenatide is combined with AICA ribonucleotide.

Bydureon Bcise Toxicity & Overdose RiskAnimal studies have shown that exenatide use during pregnancy can cause deformities in the baby’s ribs and vertebrae and slow growth. Uncontrolled high blood sugar during pregnancy has been linked to a 25% risk of miscarriage. There are no known human studies on the effects of exenatide in pregnancy and it should only be prescribed if the benefits outweigh the risks. It is not known how exenatide affects breastfed infants or pediatric patients, so the risks and benefits should be weighed carefully. Older adults may be more likely to experience side effects due to their higher risk of renal impairment or other health issues,

image of a doctor in a lab doing drug, clinical research

Bydureon Bcise Novel Uses: Which Conditions Have a Clinical Trial Featuring Bydureon Bcise?

162 active trials are currently being conducted to assess the potential of Bydureon Bcise in providing relief for Type 2 Diabetes.

Condition

Clinical Trials

Trial Phases

Type 2 Diabetes

165 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1

Diet

6 Actively Recruiting

Not Applicable

Physical Activity

42 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1